How do medical and pharmacy directors perceive the value of new cancer drugs?

Drug Benefit Trends

Volumn 21, Issue 4, 2009, Pages 120-130

  Nadler, Eric ^a   Broderick, William C ^b   Zarotsky, Victoria ^c   Kim, Jennifer ^d  

^a Baylor University   (United States)

^b Payer and Reimbursement Strategies ^*

^c Health Economics and Outcomes Research   (United States)

^d ASTRAZENECA   (United Kingdom)

Author keywords

Bevacizumab; Cancer; Cost effectiveness; Erlotinib; Sunitinib malate

Indexed keywords

BEVACIZUMAB; ERLOTINIB; FLUOROURACIL; SUNITINIB;

ADMINISTRATIVE PERSONNEL; ADVANCED CANCER; ARTICLE; CANCER SURVIVAL; COLORECTAL CANCER; COST EFFECTIVENESS ANALYSIS; HEALTH CARE COST; HEALTH CARE PERSONNEL; HEALTH CARE PLANNING; HEALTH INSURANCE; HUMAN; KIDNEY CARCINOMA; LUNG NON SMALL CELL CANCER; OVERALL SURVIVAL; PHARMACIST; PROGRESSION FREE SURVIVAL; QUALITY ADJUSTED LIFE YEAR; REIMBURSEMENT;

EID: 77955102893     PISSN: 10805826     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Pharmaceutical Research and Manufacturers of America: Medicines in Development for Cancer. 2008. http://www.phrma.org/files/meds-in-dev/Cancer2008. pdf. Accessed March 19, 2009.
2. Szabo L. Prices soar for cancer drugs. USA Today. July 11, 2006. http://www.usatoday.com/news/health/2006-07-10-cancer-costs-x.htm. Accessed March 6, 2009.
3. Bach PB. Limits on Medicare's ability to control rising spending on cancer drugs. N Engl J Med. 2009;360:626-633.
4. Minkoff NB. Colorectal cancer: complexities and challenges in managed care. J Manag Care Pharm. 2007;13(6, suppl C):S27-S29. http://www.amcp.org/data/ jmcp/Pages%2027-29.pdf. Accessed March 6, 2009.
5. Curtiss FR. Pharmacy benefit spending on oral chemotherapy drugs. J Manag Care Pharm. 2006;12:570-577. http://www.amcp.org/data/jmcp/contemporary- subjects-570-577.pdf. Accessed March 6, 2009.
6. Johnson JR, Cohen M, Sridhara R, et al. Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen. Clin Cancer Res. 2005; 11:6414-6421.
7. Ramsey SD. How should we pay the piper when he's calling the tune? On the long-term affordability of cancer care in the United States. J Clin Oncol. 2007;25:175-179.
8. Nadler E, Eckert B, Neumann PJ. Do oncologists believe new cancer drugs offer good value? Oncologist. 2006;11:90-95. (Pubitemid 43261756)
9. Lee SJ, Anasetti C, Kuntz KM, et al. The costs and cost-effectiveness of unrelated donor bone marrow transplantation for chronic phase chronic myelogenous leukemia. Blood. 1998;92:4047-4052. (Pubitemid 28544318)
10. Feldman AM, de Lissovoy G, Bristow MR, et al. Cost effectiveness of cardiac resynchronization therapy in the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) trial. J Am Coll Cardiol. 2005;46:2311-2321.
11. Chapman RH, Berger M, Weinstein MC, et al. When does quality-adjusting life-years matter in cost-effectiveness analysis? Health Econ. 2004;13:429-436. (Pubitemid 38660392)
12. Zhang P, Engelgau MM, Norris SL, et al. Application of economic analysis to diabetes and diabetes care. Ann Intern Med. 2004;140:972-977. (Pubitemid 38685289)
13. Fleming T, ed. 2006 Red Book: Pharmacy's Fundamental Reference (Red Book Drug Topics). Montvale, NJ: Thomson PDR; 2006.
14. Avastin (bevacizumab) prescribing information. Genentech BioOncology. http://www.avastin.com. Accessed March 6, 2009.
15. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335-2342.
16. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer [published correction appears in N Engl J Med. 2007;356:318]. N Engl J Med. 2006;355:2542-2550.
17. Kabbinavar FF, Hambleton J, Mass RD, et al. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol. 2005;23:3706-3712.
18. Tarceva (erlotinib) prescribing information. Genentech USA, Inc and OSI Pharmaceuticals, Inc. http://www.tarceva.com. Accessed March 6, 2009.
19. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al; National Cancer Institute of Canada Clinical Trials Group. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005;353:123-132.
20. Sutent (sunitinib malate) prescribing information. Pfizer Oncology. http://www.sutent.com. Accessed March 6, 2009.
21. Ramsey SD, Clarke L, Kamath TV, Lubeck D. Evaluation of erlotinib in advanced non-small cell lung cancer: impact on the budget of a US health insurance plan. J Manag Care Pharm. 2006;12:472-478. http://www.amcp. org/data/jmcp/form-472-478.pdf. Accessed March 6, 2009.
22. Establishing a single-source approach to measuring quality. Jt Comm Perspect. 2001;21(8):5.
23. Lipsy RJ, Fuller MG, Roski J, Mansukani S. Anticipating the future: how the emergence of innovative biologic agents impacts benefit design, utilization, and provider relations. J Manag Care Pharm. 2004;10(3 suppl):S4-S9. http://www. amcp.org/data/jmcp/MAY04%20Supplement1.pdf. Accessed March 6, 2009.